RDP58 does not prevent graft-versus-host disease after dog leukocyte antigen-nonidentical canine hematopoietic cell transplantation.
Graft-versus-host disease (GVHD) remains a cause of substantial morbidity for patients undergoing allogeneic hematopoietic cell transplantation (HCT). The present study was undertaken to investigate the effectiveness of RDP58, a peptide derived from the human leukocyte antigen class I heavy chain, in preventing GVHD in the established dog leukocyte antigen (DLA)-nonidentical canine model. Dogs underwent HCT from unrelated DLA-nonidentical donors after conditioning with 920 cGy total body irradiation. Engraftment and achievement of full donor chimerism was seen in five of six dogs, whereas one dog showed rejection and died of marrow aplasia. All five dogs with engraftment developed acute GVHD and were euthanized at an average of 20.6 days after HCT. Compared with historical controls, the Suse of RDP58 neither prevented acute GVHD nor significantly prolonged survival of DLA-nonidentical HCT recipients.
Kuhr
Christian S
CS
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. kuhrc@u.washington.edu
Lupu
Marilena
M
Little
Marie-Térèse
MT
Zellmer
Eustacia
E
Sale
George E
GE
Storb
Rainer
R
D000818:Animals; D004285:Dogs; D006086:Graft vs Host Disease / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D015395:Histocompatibility Antigens Class I / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007962:Leukocytes; D010455:Peptides / Q000627:therapeutic use*
D015395:Histocompatibility Antigens Class I; D007166:Immunosuppressive Agents; D010455:Peptides; C092373:allotrap